Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.59 |
| ▸ | CAPN1 | P07384 | 6/20 | 0.53 |
| ▸ | CTSB | P07858 | 4/20 | 0.52 |
| ▸ | CTSC | P53634 | 3/20 | 0.52 |
| ▸ | CTSH | P09668 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 1/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | ALPI | P09923 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | XIAP | P98170 | 1/20 | 0.45 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20366197 | 0.89 | CTSB (0.52) | ACECAPN1CTSBCTSCCTSL | |
| SCHEMBL20204693 | 0.88 | CTSC (0.58) | ACECAPN1CTSBCTSCCTSL | |
| SCHEMBL20204691 | 0.88 | CTSC (0.58) | ACECAPN1CTSBCTSCCTSL | |
| SCHEMBL14623960 | 0.86 | CTSB (0.54) | ACECAPN1CTSBCTSCCTSL | |
| SCHEMBL2740206 | 0.86 | CTSB (0.54) | ACECAPN1CTSBCTSCCTSL | |
| SCHEMBL23223533 | 0.85 | MMP2 (0.62) | ACECAPN1CTSB | |
| SCHEMBL19663542 | 0.85 | CAPN1 (0.58) | ACECAPN1CTSBCTSCCTSH | |
| SCHEMBL19365037 | 0.84 | CTSB (0.53) | ACECAPN1CTSBCTSCCTSL | |
| SCHEMBL3497501 | 0.84 | CTSB (0.53) | ACECAPN1CTSBCTSCCTSL | |
| SCHEMBL17521518 | 0.84 | MMP2 (0.58) | ACECAPN1CTSBCTSCCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11124498-B2 | Compositions and methods for modulating protease activity | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-09-21 | — | — | US | disclosed |
| US-20200048227-A1 | COMPOSITIONS AND METHODS FOR MODULATING PROTEASE ACTIVITY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11124498-B2 | Compositions and methods for modulating protease activity | RNASE1, ADAM8, CTRL | ACE 130/4885CAPN1 81/4885CTSB 8/4885 |
| US-20200048227-A1 | COMPOSITIONS AND METHODS FOR MODULATING PROTEASE ACTIVITY | RNASE1, ADAM8, CTRL | ACE 130/4885CAPN1 81/4885CTSB 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.